<p>Corcept Therapeutics（納斯達克代碼：CORT - 獲取免費報告）在週五發佈的研究報告中，由 Canaccord Genuity Group 的股票分析師將其目標價格從 142.00 美元下調至 137.00 美元，Benzinga 報道。該公司目前對這家生物技術公司的股票給予 “買入” 評級。Canaccord Genuity Group 的目標價格意味着該股票當前價格有 98.57% 的潛在上漲空間。</p>
<ul>
<li>3 只逆勢而上的生物製藥股票</li>
</ul>
<p>其他一些研究分析師最近也對 CORT 發佈了報告。Truist Financial 在 5 月 6 日的研究報告中將 Corcept Therapeutics 的目標價格設定為 135.00 美元。HC Wainwright 將 Corcept Therapeutics 的目標價格從 150.00 美元下調至 145.00 美元，並在 5 月 6 日的研究報告中對該股票給予 “買入” 評級。Piper Sandler 在週五的研究報告中將 Corcept Therapeutics 的目標價格從 131.00 美元下調至 121.00 美元，並對該股票給予 “增持” 評級。最後，Wall Street Zen 在 5 月 14 日的研究報告中將 Corcept Therapeutics 的評級從 “買入” 下調至 “持有”。一位分析師對該股票給予 “持有” 評級，五位分析師給予 “買入” 評級。根據 MarketBeat 的數據，Corcept Therapeutics 的共識評級為 “適度買入”，平均目標價格為 134.50 美元。</p>
<p>獲取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
<p><strong>查看我們關於 CORT 的最新報告</strong></p>
<h2>Corcept Therapeutics 價格表現</h2>
<p>週五，CORT 股票在交易時段上漲 1.82 美元，達到 68.99 美元。該股票的交易量為 645,560 股，而其平均交易量為 1,366,292 股。該公司的市值為 73.2 億美元，市盈率為 59.15，貝塔值為 0.15。該公司有 50 日簡單移動平均線為 71.81 美元，200 日簡單移動平均線為 68.21 美元。Corcept Therapeutics 的 12 個月最低價為 32.33 美元，最高價為 117.33 美元。</p>
<p>Corcept Therapeutics（納斯達克代碼：CORT - 獲取免費報告）最近於 7 月 31 日發佈了季度財報。這家生物技術公司報告本季度每股收益為 0.29 美元，超出分析師共識預期的 0.23 美元，超出幅度為 0.06 美元。Corcept Therapeutics 的淨利潤率為 19.33%，股本回報率為 20.40%。該公司本季度的收入為 1.9443 億美元，而分析師預期為 1.9940 億美元。去年同期，該公司每股收益為 0.32 美元。與去年同期相比，該公司的季度收入增長了 18.7%。平均而言，股票分析師預計 Corcept Therapeutics 今年將發佈 1.36 美元的每股收益。</p>
<h2>內部買賣</h2>
<p>在其他新聞中，首席執行官 Joseph K. Belanoff 於 7 月 17 日出售了 615 股公司的股票，交易發生在該日。股票以平均價格 73.69 美元出售，總價值為 45,319.35 美元。出售後，首席執行官直接持有該公司 2,901,370 股股票，估值約為 213,801,955.30 美元。這筆交易代表其持股比例下降了 0.02%。該交易已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。此外，內部人士 Sean Maduck 於 7 月 18 日出售了 473 股公司的股票，交易發生在該日。股票以平均價格 73.44 美元出售，總交易額為 34,737.12 美元。交易完成後，該內部人士持有 17,705 股公司股票，估值約為 1,300,255.20 美元。這筆交易代表其持股比例下降了 2.60%。該銷售的披露信息可以在這裏找到。內部人士在上個季度總共出售了價值 13,237,621 美元的 173,038 股公司股票。公司內部人士持有該公司 20.80% 的股份。</p>
<h2>機構資金流入和流出</h2>
<p>大型投資者最近增加或減少了對該公司的持股。Brooklyn Investment Group 在第一季度將其在 Corcept Therapeutics 的股份增加了 99.5%。Brooklyn Investment Group 現在擁有 373 股生物技術公司的股票，估值為 43,000 美元，此前在上個季度又增持了 186 股。MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在 Corcept Therapeutics 的股份增加了 102.0%。MassMutual Private Wealth &amp; Trust FSB 現在擁有 620 股生物技術公司的股票，估值為 71,000 美元，此前在上個季度又增持了 313 股。Covestor Ltd 在第一季度將其在 Corcept Therapeutics 的持股增加了 1,741.2%。Covestor Ltd 現在擁有 626 股生物技術公司的股票，價值 72,000 美元，此前在上個季度又增持了 592 股。IFP Advisors Inc 在第一季度將其在 Corcept Therapeutics 的持股增加了 1,150.8%。IFP Advisors Inc 現在擁有 738 股生物技術公司的股票，價值 84,000 美元，此前在上個季度又增持了 679 股。最後，USA Financial Formulas 在第二季度購買了 Corcept Therapeutics 的新股份，價值約為 56,000 美元。機構投資者持有該公司 93.61% 的股份。</p>
<h2>Corcept Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Corcept Therapeutics Incorporated 在美國從事用於治療嚴重內分泌、腫瘤、代謝和神經系統疾病的藥物的發現和開發。它提供 Korlym 片劑，用於治療因內源性庫欣綜合症導致的高血糖症，適用於成年患者；以及患有 2 型糖尿病或葡萄糖耐受不良且未能接受手術或不適合手術的患者。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而非 Corcept Therapeutics</li>
<li>現在可以購買的兩隻金融科技股票和一隻需要避免的股票</li>
<li>Rocket Lab 下週報告：投資者需要知道的事項</li>
<li>零售投資者如何交易多倫多證券交易所 (TSX)？</li>
<li>蘋果股票：大盈利，小波動——是時候購買了嗎？</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>亞馬遜的盈利：接下來會發生什麼以及如何應對</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Corcept Therapeutics 嗎？</h2>
<p>在考慮 Corcept Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Corcept Therapeutics 並不在名單上。</p>
<p>雖然 Corcept Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Corcept醫療

<p>Canaccord Genuity Group 已將 Corcept Therapeutics（NASDAQ:CORT）的目標股價從 142.00 美元下調至 137.00 美元，同時維持 “買入” 評級。這個新目標暗示從當前股價來看，潛在上漲幅度為 98.57%。其他分析師也調整了他們的目標股價，普遍評級為 “適度買入”，平均目標價為 134.50 美元。Corcept 的股票最近交易價格為 68.99 美元，市值為 73.2 億美元，市盈率為 59.15</p>

<p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) had its price objective cut by stock analysts at Canaccord Genuity Group from $142.00 to $137.00 in a research note issued on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the biotechnology company's stock. Canaccord Genuity Group's target price would indicate a potential upside of 98.57% from the stock's current price.</p>
<div class="lb-trans"><p>Corcept Therapeutics（納斯達克代碼：CORT - 獲取免費報告）在週五發佈的研究報告中，由 Canaccord Genuity Group 的股票分析師將其目標價格從 142.00 美元下調至 137.00 美元，Benzinga 報道。該公司目前對這家生物技術公司的股票給予 “買入” 評級。Canaccord Genuity Group 的目標價格意味着該股票當前價格有 98.57% 的潛在上漲空間。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只逆勢而上的生物製藥股票</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on CORT. Truist Financial set a $135.00 target price on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. HC Wainwright cut their target price on shares of Corcept Therapeutics from $150.00 to $145.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, May 6th. Piper Sandler cut their target price on shares of Corcept Therapeutics from $131.00 to $121.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday. Finally, Wall Street Zen cut shares of Corcept Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Corcept Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $134.50.</p>
<div class="lb-trans"><p>其他一些研究分析師最近也對 CORT 發佈了報告。Truist Financial 在 5 月 6 日的研究報告中將 Corcept Therapeutics 的目標價格設定為 135.00 美元。HC Wainwright 將 Corcept Therapeutics 的目標價格從 150.00 美元下調至 145.00 美元，並在 5 月 6 日的研究報告中對該股票給予 “買入” 評級。Piper Sandler 在週五的研究報告中將 Corcept Therapeutics 的目標價格從 131.00 美元下調至 121.00 美元，並對該股票給予 “增持” 評級。最後，Wall Street Zen 在 5 月 14 日的研究報告中將 Corcept Therapeutics 的評級從 “買入” 下調至 “持有”。一位分析師對該股票給予 “持有” 評級，五位分析師給予 “買入” 評級。根據 MarketBeat 的數據，Corcept Therapeutics 的共識評級為 “適度買入”，平均目標價格為 134.50 美元。</p>
</div><p>Get <strong>Corcept Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on CORT</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CORT 的最新報告</strong></p>
</div><h2>Corcept Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Corcept Therapeutics 價格表現</h2>
</div><p>Shares of CORT stock traded up $1.82 during trading hours on Friday, reaching $68.99. The stock had a trading volume of 645,560 shares, compared to its average volume of 1,366,292. The firm has a market capitalization of $7.32 billion, a PE ratio of 59.15 and a beta of 0.15. The firm has a 50-day simple moving average of $71.81 and a 200-day simple moving average of $68.21. Corcept Therapeutics has a twelve month low of $32.33 and a twelve month high of $117.33.</p>
<div class="lb-trans"><p>週五，CORT 股票在交易時段上漲 1.82 美元，達到 68.99 美元。該股票的交易量為 645,560 股，而其平均交易量為 1,366,292 股。該公司的市值為 73.2 億美元，市盈率為 59.15，貝塔值為 0.15。該公司有 50 日簡單移動平均線為 71.81 美元，200 日簡單移動平均線為 68.21 美元。Corcept Therapeutics 的 12 個月最低價為 32.33 美元，最高價為 117.33 美元。</p>
</div><p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. Corcept Therapeutics had a net margin of 19.33% and a return on equity of 20.40%. The company had revenue of $194.43 million for the quarter, compared to analyst estimates of $199.40 million. During the same quarter last year, the firm posted $0.32 earnings per share. The company's quarterly revenue was up 18.7% compared to the same quarter last year. On average, equities analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>Corcept Therapeutics（納斯達克代碼：CORT - 獲取免費報告）最近於 7 月 31 日發佈了季度財報。這家生物技術公司報告本季度每股收益為 0.29 美元，超出分析師共識預期的 0.23 美元，超出幅度為 0.06 美元。Corcept Therapeutics 的淨利潤率為 19.33%，股本回報率為 20.40%。該公司本季度的收入為 1.9443 億美元，而分析師預期為 1.9940 億美元。去年同期，該公司每股收益為 0.32 美元。與去年同期相比，該公司的季度收入增長了 18.7%。平均而言，股票分析師預計 Corcept Therapeutics 今年將發佈 1.36 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, CEO Joseph K. Belanoff sold 615 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $73.69, for a total value of $45,319.35. Following the sale, the chief executive officer directly owned 2,901,370 shares in the company, valued at approximately $213,801,955.30. This trade represents a 0.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 473 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $73.44, for a total transaction of $34,737.12. Following the completion of the transaction, the insider owned 17,705 shares of the company's stock, valued at approximately $1,300,255.20. This trade represents a 2.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 173,038 shares of company stock worth $13,237,621 in the last quarter. Corporate insiders own 20.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 Joseph K. Belanoff 於 7 月 17 日出售了 615 股公司的股票，交易發生在該日。股票以平均價格 73.69 美元出售，總價值為 45,319.35 美元。出售後，首席執行官直接持有該公司 2,901,370 股股票，估值約為 213,801,955.30 美元。這筆交易代表其持股比例下降了 0.02%。該交易已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。此外，內部人士 Sean Maduck 於 7 月 18 日出售了 473 股公司的股票，交易發生在該日。股票以平均價格 73.44 美元出售，總交易額為 34,737.12 美元。交易完成後，該內部人士持有 17,705 股公司股票，估值約為 1,300,255.20 美元。這筆交易代表其持股比例下降了 2.60%。該銷售的披露信息可以在這裏找到。內部人士在上個季度總共出售了價值 13,237,621 美元的 173,038 股公司股票。公司內部人士持有該公司 20.80% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. Brooklyn Investment Group increased its stake in shares of Corcept Therapeutics by 99.5% in the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 186 shares in the last quarter. MassMutual Private Wealth &amp; Trust FSB increased its stake in Corcept Therapeutics by 102.0% during the 1st quarter. MassMutual Private Wealth &amp; Trust FSB now owns 620 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 313 shares in the last quarter. Covestor Ltd boosted its holdings in Corcept Therapeutics by 1,741.2% during the first quarter. Covestor Ltd now owns 626 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 592 shares during the last quarter. IFP Advisors Inc boosted its holdings in Corcept Therapeutics by 1,150.8% during the first quarter. IFP Advisors Inc now owns 738 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 679 shares during the last quarter. Finally, USA Financial Formulas purchased a new position in shares of Corcept Therapeutics in the 2nd quarter worth about $56,000. Institutional investors own 93.61% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該公司的持股。Brooklyn Investment Group 在第一季度將其在 Corcept Therapeutics 的股份增加了 99.5%。Brooklyn Investment Group 現在擁有 373 股生物技術公司的股票，估值為 43,000 美元，此前在上個季度又增持了 186 股。MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在 Corcept Therapeutics 的股份增加了 102.0%。MassMutual Private Wealth &amp; Trust FSB 現在擁有 620 股生物技術公司的股票，估值為 71,000 美元，此前在上個季度又增持了 313 股。Covestor Ltd 在第一季度將其在 Corcept Therapeutics 的持股增加了 1,741.2%。Covestor Ltd 現在擁有 626 股生物技術公司的股票，價值 72,000 美元，此前在上個季度又增持了 592 股。IFP Advisors Inc 在第一季度將其在 Corcept Therapeutics 的持股增加了 1,150.8%。IFP Advisors Inc 現在擁有 738 股生物技術公司的股票，價值 84,000 美元，此前在上個季度又增持了 679 股。最後，USA Financial Formulas 在第二季度購買了 Corcept Therapeutics 的新股份，價值約為 56,000 美元。機構投資者持有該公司 93.61% 的股份。</p>
</div><h2>Corcept Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Corcept Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.</p>
<div class="lb-trans"><p>Corcept Therapeutics Incorporated 在美國從事用於治療嚴重內分泌、腫瘤、代謝和神經系統疾病的藥物的發現和開發。它提供 Korlym 片劑，用於治療因內源性庫欣綜合症導致的高血糖症，適用於成年患者；以及患有 2 型糖尿病或葡萄糖耐受不良且未能接受手術或不適合手術的患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Corcept Therapeutics</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Rocket Lab Reports Next Week: Here’s What Investors Should Know</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Apple Stock: Big Earnings, Small Move—Time to Buy?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Amazon's Earnings: What Comes Next and How to Play It</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Corcept Therapeutics</li>
<li>現在可以購買的兩隻金融科技股票和一隻需要避免的股票</li>
<li>Rocket Lab 下週報告：投資者需要知道的事項</li>
<li>零售投資者如何交易多倫多證券交易所 (TSX)？</li>
<li>蘋果股票：大盈利，小波動——是時候購買了嗎？</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>亞馬遜的盈利：接下來會發生什麼以及如何應對</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CORT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Corcept Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Corcept Therapeutics 嗎？</h2>
</div><p>Before you consider Corcept Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Corcept Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Corcept Therapeutics 並不在名單上。</p>
</div><p>While Corcept Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corcept Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Canaccord Genuity Group 的分析師將 Corcept Therapeutics（納斯達克股票代碼：CORT）的目標股價下調至 137.00 美元